Pirtobrutinib in relapsed or refractory mantle cell lymphoma: a profile of its use

<div><strong>Funding</strong> The preparation of this review was not supported by any external funding.</div> <div><strong>Authorship and Conflict of interest</strong> Young-A Heo, a salaried employee of Adis International Ltd/Springer Nature and an editor of <em>Drugs & Therapy Perspectives, </em>was not involved in any publishing decisions for the manuscript and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.  </div> <div><strong>Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability</strong> not applicable</div> <p>Additional information about this Adis Drug Review can be found <a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews" target="_blank">here</a></p> <p>Abstract</p> <p>Pirtobrutinib (Jaypirca^®), an oral, small molecule, non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, is a promising new treatment option for patients with relapsed or refractory mantle cell lymphoma (MCL), including those who had received a covalent BTK inhibitor. In a multicentre, open-label, phase 1/2 BRUIN trial, pirtobrutinib demonstrated meaningful response rates and durable efficacy in patients with heavily pretreated (including a covalent BTK inhibitor) relapsed or refractory MCL. Pirtobrutinib had a manageable tolerability profile, with most treatment related adverse events being mild to moderate in severity. Longer term, the tolerability profile of pirtobrutinib revealed no new safety signals.  </p> <p>  </p> <div><strong>©</strong> Springer Nature Switzerland AG 2024</div>